-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Maze Therapeutics, Raises Price Target to $49

Benzinga·11/10/2026 15:15:12
Listen to the news
Wedbush analyst Laura Chico maintains Maze Therapeutics (NASDAQ:MAZE) with a Outperform and raises the price target from $48 to $49.